Cusan L - Search Results

1

Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy.

Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Têtu B, Fradet Y, Candas B. Labrie F, et al. Among authors: cusan l. Cancer Surv. 1995;23:149-56. Cancer Surv. 1995. PMID: 7621455 Clinical Trial.

2

Combination therapy with flutamide and castration (orchiectomy or LH-RH agonist) in untreated patients with advanced prostate cancer.

Dupont A, Labrie F, Cusan L, Gomez JL, Tremblay M, Lacourcière Y, Emond J, Monfette G. Dupont A, et al. Among authors: cusan l. Recent Results Cancer Res. 1992;124:43-54. doi: 10.1007/978-88-470-2186-0_5. Recent Results Cancer Res. 1992. PMID: 1615218 No abstract available.

3

Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience.

Labrie F, Dupont A, Cusan L, Gomez J, Emond J, Monfette G. Labrie F, et al. Among authors: cusan l. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):943-50. doi: 10.1016/0960-0760(90)90448-t. J Steroid Biochem Mol Biol. 1990. PMID: 2285608 Clinical Trial.

4

Metastatic prostate cancer pulmonary nodules: beneficial effects of combination therapy and subsequent withdrawal of flutamide.

Cusan L, Gomez JL, Dupont A, Diamond P, Lemay M, Moore S, Labrie F. Cusan L, et al. Prostate. 1994 May;24(5):257-61. doi: 10.1002/pros.2990240507. Prostate. 1994. PMID: 7513417

5

Combination of screening and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality.

Labrie F, Cusan L, Gomez JL, Diamond P, Candas B. Labrie F, et al. Among authors: cusan l. J Clin Endocrinol Metab. 1995 Jul;80(7):2002-13. doi: 10.1210/jcem.80.7.7541800. J Clin Endocrinol Metab. 1995. PMID: 7541800 Review.

6

Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy.

Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F. Dupont A, et al. Among authors: cusan l. J Urol. 1993 Sep;150(3):908-13. doi: 10.1016/s0022-5347(17)35646-x. J Urol. 1993. PMID: 7688437

7

Stratification of stage D2 prostate cancer patients by a disease aggressiveness score and its use in evaluating disease response and outcome to combination hormonal treatment (GnRH-A plus flutamide).

Koutsilieris M, Dupont A, Gomez J, Cusan L, Suburu R, Diamond P, Labrie F. Koutsilieris M, et al. Among authors: cusan l. Anticancer Res. 1994 Mar-Apr;14(2B):627-34. Anticancer Res. 1994. PMID: 8010719 Clinical Trial.

8

Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer.

Labrie F, Dupont A, Cusan L, Gomez JL, Diamond P. Labrie F, et al. Among authors: cusan l. Clin Invest Med. 1993 Dec;16(6):493-8. Clin Invest Med. 1993. PMID: 8013154 Clinical Trial.

9

Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.

Labrie F, Dupont A, Cusan L, Gomez J, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Têtu B, et al. Labrie F, et al. Among authors: cusan l. Clin Invest Med. 1993 Dec;16(6):499-509. Clin Invest Med. 1993. PMID: 8013155 Clinical Trial.

10

Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study.

Vailancourt L, Ttu B, Fradet Y, Dupont A, Gomez J, Cusan L, Suburu ER, Diamond P, Candas B, Labrie F. Vailancourt L, et al. Among authors: cusan l. Am J Surg Pathol. 1996 Jan;20(1):86-93. doi: 10.1097/00000478-199601000-00010. Am J Surg Pathol. 1996. PMID: 8540613 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

129 results

Search Page

Filters